166 related articles for article (PubMed ID: 38580347)
1. Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1-phase 2a study.
Barde F; Lorenzon R; Vicaut E; Rivière S; Cacoub P; Cacciatore C; Rosenzwajg M; Daguenel-Nguyen A; Fain O; Klatzmann D; Mekinian A
RMD Open; 2024 Apr; 10(2):. PubMed ID: 38580347
[TBL] [Abstract][Full Text] [Related]
2. The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial.
Lorenzon R; Ribet C; Pitoiset F; Aractingi S; Banneville B; Beaugerie L; Berenbaum F; Cacoub P; Champey J; Chazouilleres O; Corpechot C; Fautrel B; Mekinian A; Regnier E; Saadoun D; Salem JE; Sellam J; Seksik P; Vicaut E; Rosenzwajg M; Klatzmann D
J Autoimmun; 2024 Apr; 144():103172. PubMed ID: 38330545
[TBL] [Abstract][Full Text] [Related]
3. Absolute decrease in regulatory T cells and low-dose interleukin-2 therapy: restoring and expanding regulatory T cells to treat systemic sclerosis: a 24-week study.
Yu Z; Cheng H; Ding T; Liang Y; Yan C; Gao C; Wen H
Clin Exp Dermatol; 2022 Dec; 47(12):2188-2195. PubMed ID: 36184784
[TBL] [Abstract][Full Text] [Related]
4. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.
Rosenzwajg M; Lorenzon R; Cacoub P; Pham HP; Pitoiset F; El Soufi K; RIbet C; Bernard C; Aractingi S; Banneville B; Beaugerie L; Berenbaum F; Champey J; Chazouilleres O; Corpechot C; Fautrel B; Mekinian A; Regnier E; Saadoun D; Salem JE; Sellam J; Seksik P; Daguenel-Nguyen A; Doppler V; Mariau J; Vicaut E; Klatzmann D
Ann Rheum Dis; 2019 Feb; 78(2):209-217. PubMed ID: 30472651
[TBL] [Abstract][Full Text] [Related]
5. Correlation of Th17 cells and CD4⁺CD25⁺ regulatory T cells with clinical parameters in patients with systemic sclerosis.
Jiang N; Li M; Zeng X
Chin Med J (Engl); 2014; 127(20):3557-61. PubMed ID: 25316229
[TBL] [Abstract][Full Text] [Related]
6. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.
Rosenzwajg M; Salet R; Lorenzon R; Tchitchek N; Roux A; Bernard C; Carel JC; Storey C; Polak M; Beltrand J; Amouyal C; Hartemann A; Corbeau P; Vicaut E; Bibal C; Bougnères P; Tran TA; Klatzmann D
Diabetologia; 2020 Sep; 63(9):1808-1821. PubMed ID: 32607749
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis.
MacDonald KG; Dawson NAJ; Huang Q; Dunne JV; Levings MK; Broady R
J Allergy Clin Immunol; 2015 Apr; 135(4):946-955.e9. PubMed ID: 25678090
[TBL] [Abstract][Full Text] [Related]
8. Regulatory T Cells in Systemic Sclerosis.
Frantz C; Auffray C; Avouac J; Allanore Y
Front Immunol; 2018; 9():2356. PubMed ID: 30374354
[TBL] [Abstract][Full Text] [Related]
9. Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.
Todd JA; Evangelou M; Cutler AJ; Pekalski ML; Walker NM; Stevens HE; Porter L; Smyth DJ; Rainbow DB; Ferreira RC; Esposito L; Hunter KM; Loudon K; Irons K; Yang JH; Bell CJ; Schuilenburg H; Heywood J; Challis B; Neupane S; Clarke P; Coleman G; Dawson S; Goymer D; Anselmiova K; Kennet J; Brown J; Caddy SL; Lu J; Greatorex J; Goodfellow I; Wallace C; Tree TI; Evans M; Mander AP; Bond S; Wicker LS; Waldron-Lynch F
PLoS Med; 2016 Oct; 13(10):e1002139. PubMed ID: 27727279
[TBL] [Abstract][Full Text] [Related]
10. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial.
Camu W; Mickunas M; Veyrune JL; Payan C; Garlanda C; Locati M; Juntas-Morales R; Pageot N; Malaspina A; Andreasson U; Kirby J; Suehs C; Saker S; Masseguin C; De Vos J; Zetterberg H; Shaw PJ; Al-Chalabi A; Leigh PN; Tree T; Bensimon G
EBioMedicine; 2020 Sep; 59():102844. PubMed ID: 32651161
[TBL] [Abstract][Full Text] [Related]
11. Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions.
Mathian A; Parizot C; Dorgham K; Trad S; Arnaud L; Larsen M; Miyara M; Hié M; Piette JC; Frances C; Yssel H; Amoura Z; Gorochov G
Ann Rheum Dis; 2012 Jul; 71(7):1227-34. PubMed ID: 22696687
[TBL] [Abstract][Full Text] [Related]
12. Higher levels of serum interleukin-35 are associated with the severity of pulmonary fibrosis and Th2 responses in patients with systemic sclerosis.
Tang J; Lei L; Pan J; Zhao C; Wen J
Rheumatol Int; 2018 Aug; 38(8):1511-1519. PubMed ID: 29846790
[TBL] [Abstract][Full Text] [Related]
13. The Pathophysiological Roles of Regulatory T Cells in the Early Phase of Systemic Sclerosis.
Kobayashi S; Nagafuchi Y; Shoda H; Fujio K
Front Immunol; 2022; 13():900638. PubMed ID: 35686127
[TBL] [Abstract][Full Text] [Related]
14. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea.
Antiga E; Quaglino P; Bellandi S; Volpi W; Del Bianco E; Comessatti A; Osella-Abate S; De Simone C; Marzano A; Bernengo MG; Fabbri P; Caproni M
Br J Dermatol; 2010 May; 162(5):1056-63. PubMed ID: 20105169
[TBL] [Abstract][Full Text] [Related]
15. Effects of thalidomide on Th17, Treg cells and TGF-β1/Smad3 pathway in a mouse model of systemic sclerosis.
Lu Y; Zhao C; Lei L; Tao Z; Zheng L; Wen J; Li X
Int J Rheum Dis; 2020 Mar; 23(3):406-419. PubMed ID: 31840939
[TBL] [Abstract][Full Text] [Related]
16. [THE ROLE OF SEMAPHORIN 7A IN SYSTEMIC SCLEROSIS].
Rimar D; Slobodin G; Rosner I; Rozenbaum M; Kaly L; Boulman N; Jiries N; Awisat A; Vadasz Z
Harefuah; 2017 Jul; 156(7):418-421. PubMed ID: 28786275
[TBL] [Abstract][Full Text] [Related]
17. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.
Saadoun D; Rosenzwajg M; Joly F; Six A; Carrat F; Thibault V; Sene D; Cacoub P; Klatzmann D
N Engl J Med; 2011 Dec; 365(22):2067-77. PubMed ID: 22129253
[TBL] [Abstract][Full Text] [Related]
18. Targeting Costimulatory Pathways in Systemic Sclerosis.
Boleto G; Allanore Y; Avouac J
Front Immunol; 2018; 9():2998. PubMed ID: 30619351
[TBL] [Abstract][Full Text] [Related]
19. Elevated levels of CD4(+)CD25(+)FoxP3(+) T cells in systemic sclerosis patients contribute to the secretion of IL-17 and immunosuppression dysfunction.
Liu X; Gao N; Li M; Xu D; Hou Y; Wang Q; Zhang G; Sun Q; Zhang H; Zeng X
PLoS One; 2013; 8(6):e64531. PubMed ID: 23776439
[TBL] [Abstract][Full Text] [Related]
20. Increased proportions of functionally impaired regulatory T cell subsets in systemic sclerosis.
Ugor E; Simon D; Almanzar G; Pap R; Najbauer J; Németh P; Balogh P; Prelog M; Czirják L; Berki T
Clin Immunol; 2017 Nov; 184():54-62. PubMed ID: 28522286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
